Tag:
lupus
Latest Headlines
Latest Headlines
Glaxo goes hostile on HGS with $2.6B bid
Prepare yourself for a drawn-out buyout battle--and lots of debate about the lupus treatment Benlysta.
UPDATED: GSK puts Human Genome Sciences in play with $2.59B buyout offer
In moments speculators bid up HGS's battered share value by 110%, to more than $15, as HGS quickly rejected the offer.
Anthera slashes jobs over failed cardiac trial, shifts focus to lupus drug
Days after announcing it halted a late-stage Phase III trial of its lead drug over struggles to prove its efficacy, the company disclosed it will eliminate about 45% of its workforce.
Vascular markers support lupus treatment
Lupus nephritis, or kidney inflammation, is a complication of systemic lupus erythematosus (SLE or lupus). Patients can have flares of lupus nephritis, and these may lead to chronic kidney disease.
Researchers find two potential lupus vax treatments
After 5 decades without a new treatment, lupus patients got a reprieve in March with Human Genome Sciences' Benlysta. But doctors believe there are still better options down the pipeline for patients
Analyst: Benlysta's shortcomings offer blockbuster opening for new lupus drugs
Any drug developers looking to push a late-stage program for lupus may want to pay close attention to a new note from Citi analyst Yaron Werber covering some unexpected problems for Human Genome
FDA hands GSK, Human Genome Sciences landmark Benlysta approval
The FDA has delivered a widely anticipated approval for the lupus drug Benlysta, unleashing a small army of reps as Human Genome Sciences ( $HGSI ) and GlaxoSmithKline ( $GSK ) set out to try and deliver
GSK's Witty looks to new blockbusters to reverse a bleak trend
GlaxoSmithKline's ( $GSK ) track record over the last few years has elicited few cheers. Its pipeline has failed to produce, the FDA throws up new hurdles and CEO Andrew Witty ( photo ) has to hear the
HGS shares dip on FDA delay
Shares of Human Genome Sciences took a small hit Friday evening after the biotech company said that the FDA was extending its review time for the closely-watched lupus drug benlysta. While the drug
Cracked vials force Anthera ($ANTH) to suspend PhIIb lupus study
Hayward, CA-based Anthera Pharmaceuticals ( $ANTH ) announced this morning that it is suspending dosing and enrollment in a Phase IIb study of its experimental lupus drug after a clinical investigator
